Novartis, Lilly, GSK, J&J, Sanofi-Aventis Make Gains On Japan NHI Listing
This article was originally published in PharmAsia News
Executive Summary
TOKYO - At the recommendation of the Central Social Insurance Medical Council, known as Chuikyo in Japanese, the Ministry of Health, Labor and Welfare has approved nine composites for the National Health Insurance reimbursement listing effective June 19, an MHLW Insurance Bureau official confirmed
You may also be interested in...
Astellas Gears Up To Launch Caduet With Pfizer; Ramps Up Oncology Franchise With Seattle Genetics Agreement
Pfizer Japan and Tokyo-based Astellas announced Nov. 26 that that they will launch combo drug Caduet (amlodipine/atorvastatin) in Japan Dec. 2
Astellas Gears Up To Launch Caduet With Pfizer; Ramps Up Oncology Franchise With Seattle Genetics Agreement
Pfizer Japan and Tokyo-based Astellas announced Nov. 26 that that they will launch combo drug Caduet (amlodipine/atorvastatin) in Japan Dec. 2
Pfizer And Astellas Ink Co-promotion Agreement For Hypertension And Cholesterol Combo Drug Caduet In Japan
TOKYO - Pfizer and Astellas Pharma have signed a co-promotion agreement for combination drug, Caduet (amlodipine and atorvastatin) for local Japanese distribution to treat both hypertension and hypercholesterolemia, the first combination drug for the two treatments, the two companies announced Aug. 26